Trends in mortality of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in southeastern Brazil

Abstract

ObjectiveTo evaluate trends in mortality among adults with myeloid leukemia in the Vale do Paraíba, State of São Paulo.MethodsData from the Brazilian National Health Service database DATASUS provided the number of deaths caused by myeloid leukemia and the number of inhabitants per year in the Regional Health Division XVII from 1994 to 2011. Registries were categorized according to gender into four age ranges (over 20 years, 20–49, 50–69 and over 70 years) for an estimation of the annual percent change for age-adjusted mortality rates. The percent changes were calculated using the Joinpoint regression analysis model.ResultsOverall, a significant decline per year was demonstrated for the entire sample (over 20 years) across the 18-year period studied (annual percent change: −5.59%; 95% CI: −8.5 to −2.5% for males; p-value < 0.05 and −7.02%; 95% CI −11.2 to −2.8% for females; p-value < 0.05) with no significant difference between genders. In an analysis using two Joinpoints, significant drops were observed from 1994 to 2001 (annual percent change: −21.22%; 95% confidence interval: −27.9 to −13.9%; p-value < 0.05) and from 1994 to 2003 (annual percent change: −12.86%; 95% confidence interval −22.2 to −2.5%; p-value < 0.05) for men and women, respectively. The declining trends were greatest for patients aged over 70 years with the age-adjusted mortality rates in younger groups declining non-significantly except for males aged 50–69 years old.ConclusionOur data suggest a significant decline per year in age-adjusted mortality rates of adult patients diagnosed with myeloid leukemia from 1994 to 2011 in the Vale do Paraíba, State of São Paulo.

Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia

“…In any case, for myeloablative HSCT outcomes in AML, the stage of the disease, early (CR1), intermediate (CR2 or beyond), and advanced (relapsed or refractory) still is a strong predictor for survival. The Brazilian centers that report to CIBMTR have overall very similar outcomes, as AML treatment results are getting better in the country . However, it is important to point out that HSCT is not recommended to all cases of AML in CR1.…”

Uvangoletin induces mitochondria-mediated apoptosis in HL-60 cells in vitro and in vivo without adverse reactions of myelosuppression, leucopenia and gastrointestinal tract disturbances

“…Leukemia is one of the leading causes correlated with death of people with malignant cancer (4). Although the diagnosis and therapy of leukemia are rapidly developed (5), there is still high mortality in leukemia patients (6,7).…”

Myeloid leukemia: are we getting better?

“…The study by Callera et al, published in this issue of the Revista Brasileira de Hematologia e Hemoterapia (RBHH), 1 reveals evidence of a continuous decrease in the mortality rate in adult patients with myeloid leukemias from 1994 to 2011 in southeast Brazil. Undoubtedly, this decline is related to the better understanding and treatment of chronic myeloid leukemia (CML), acute myeloid leukemia (AML) and promyelocytic leukemia (APL, M3).…”